BioMarin Pharmaceutical Inc.
BMRN
$58.58
$0.510.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 156.15% | 154.99% | 154.62% | 119.21% | 156.61% |
| Total Depreciation and Amortization | -21.73% | -13.45% | -7.63% | -2.35% | 5.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.19% | 47.28% | 18.85% | 57.07% | 21.37% |
| Change in Net Operating Assets | -27.50% | 10.57% | 35.70% | 8.79% | -14.20% |
| Cash from Operations | 133.16% | 149.95% | 259.69% | 199.29% | 103.96% |
| Capital Expenditure | 26.73% | 22.63% | 11.65% | 8.36% | 11.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.60% | 6,816.65% | 1,624.87% | 3,539.62% | 95.99% |
| Cash from Investing | 156.25% | 228.30% | 222.70% | 95.17% | 56.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -30,370.76% | -48,909.37% | -- | -50,923.40% | 152.44% |
| Issuance of Common Stock | -63.49% | -24.02% | -28.95% | -29.74% | -38.05% |
| Repurchase of Common Stock | 17.67% | 11.30% | -1.63% | -0.77% | 3.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -35.42% | -37.24% | 72.48% | 85.35% | 87.98% |
| Cash from Financing | -2,580.95% | -2,414.36% | -2,711.17% | -2,672.84% | -94.13% |
| Foreign Exchange rate Adjustments | -237.20% | -50.53% | 269.27% | -126.28% | 54.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.00% | 80.81% | 513.53% | -560.13% | 272.45% |